


The burden of antimicrobial resistance (AMR) in Niger

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **6,000 lives** have been lost each year since 1990 in Niger due to AMR.
- In 2021, there were an estimated **5,540 UI (3,710-7,360)** deaths attributable to AMR and **26,200 UI (18,000-34,400)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **under 5** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Escherichia coli* resistant to beta lactam / beta-lactamase inhibitors, *Klebsiella pneumoniae* resistant to beta lactam / beta-lactamase inhibitors and *Acinetobacter baumannii* resistant to anti-pseudomonal penicillin / beta-lactamase inhibitors.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in figure 2) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Niger, a 10% reduction means to decrease the number of deaths associated with AMR to **25,000**, but currently the trend for this country could reach up to **34,900 UI [22,800-53,200]** AMR-associated deaths in 2030.

AMR in Niger

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Niger between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In Niger in 2021, there were an estimated **5,540 UI (3,710-7,360)** deaths attributable to AMR and **26,200 UI (18,000-34,400)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Niger was among the highest 10 countries in** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant		Associated		Attributable	
	Bacteria (UI)	Change	Bacteria (UI)	Change	Bacteria (UI)	Change
	Mycobacterium tuberculosis 6,570 UI (3,520-9,620)	↓	Escherichia coli 5,410 UI (3,350-7,470)	↓	Klebsiella pneumoniae 1,090 UI (753-1,420)	↑
	Streptococcus pneumoniae 5,950 UI (4,070-7,830)	↓	Streptococcus pneumoniae 4,860 UI (3,170-6,560)	↓	Escherichia coli 1,030 UI (527-1,520)	↓
	Escherichia coli 5,640 UI (3,510-7,770)	↓	Klebsiella pneumoniae 4,670 UI (3,420-5,920)	↑	Acinetobacter baumannii 718 UI (538-898)	↑
	Klebsiella pneumoniae 5,070 UI (3,730-6,410)	↑	Acinetobacter baumannii 1,990 UI (1,410-2,570)	↑	Streptococcus pneumoniae 688 UI (369-1,010)	↓
	Non-typhoidal Salmonella 3,880 UI (1,630-6,130)	↑	Pseudomonas aeruginosa 1,980 UI (1,330-2,640)	↑	Pseudomonas aeruginosa 480 UI (302-657)	↑
	Pseudomonas aeruginosa 3,050 UI (2,240-3,860)	↑	Staphylococcus aureus 1,740 UI (1,010-2,460)	↑	Staphylococcus aureus 413 UI (211-616)	↑
	Staphylococcus aureus 2,620 UI (1,920-3,310)	↑	Group B Streptococcus 867 UI (552-1,180)	↑	Serratia spp. 219 UI (152-286)	↑
	Acinetobacter baumannii 2,370 UI (1,720-3,010)	↑	Serratia spp. 753 UI (527-978)	↑	Haemophilus influenzae 179 UI (83-276)	↓
	Group B Streptococcus 1,730 UI (1,240-2,220)	↑	Haemophilus influenzae 740 UI (362-1,120)	↓	Enterobacter spp. 168 UI (125-211)	↑
	Haemophilus influenzae 986 UI (694-1,280)	↓	Non-typhoidal Salmonella 601 UI (230-972)	↑	Group B Streptococcus 128 UI (62-193)	↑

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (red), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (orange), 3% to 5% (brown)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden Rank	Associated		Attributable	
	Combination (UI)	Change	Combination (UI)	Change
	Escherichia coli Aminopenicillin 5,460 UI (3,370-7,550)	↓	Escherichia coli Beta-Lactam/Lactamase Inhib. 319 UI (22-616)	↓
	Escherichia coli TMP-SMX 4,450 UI (2,800-6,100)	↓	Acinetobacter baumannii Anti-pseudomonal 240 UI (181-299)	↑
	Streptococcus pneumoniae TMP-SMX 4,430 UI (2,840-6,030)	↓	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib. 235 UI (74-395)	↓
	Klebsiella pneumoniae TMP-SMX 4,390 UI (3,210-5,580)	↑	Klebsiella pneumoniae Aminoglycosides 226 UI (144-308)	↑
	Escherichia coli Beta-Lactam/Lactamase Inhib. 4,390 UI (2,700-6,080)	↓	Staphylococcus aureus Methicillin 223 UI (70-376)	↑
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib. 4,320 UI (3,110-5,530)	↑	Escherichia coli Aminoglycosides 214 UI (65-364)	↓
	Klebsiella pneumoniae Aminoglycosides 3,540 UI (2,530-4,560)	↑	Klebsiella pneumoniae Fluoroquinolones 201 UI (113-289)	↑
	Klebsiella pneumoniae Fluoroquinolones 2,950 UI (1,970-3,940)	↑	Klebsiella pneumoniae TMP-SMX 182 UI (91-272)	↓
	Escherichia coli Aminoglycosides 2,660 UI (1,190-4,120)	↓	Streptococcus pneumoniae Fluoroquinolones 173 UI (34-313)	↓
	Streptococcus pneumoniae Macrolides 2,440 UI (1,380-3,490)	↓	Escherichia coli TMP-SMX 172 UI (116-229)	↓

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (red), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (orange), 3% to 5% (brown)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (19,500 UI (13,900-25,100)), bloodstream infections (17,900 UI (12,700-23,000)), diarrhea (16,700 UI (10,100-23,200)), tuberculosis (6,570 UI (3,520-9,620)) and meningitis (4,610 UI (2,600-6,620)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Niger, people aged under 5 saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that under 5 continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the under 5 was 16,900 UI (11,300-22,600), whereas the mortality rate per 100,000 was 990 UI (747-1,230).

Data sources for Niger

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Niger by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	1990-2021	789	Study-year datapoints
Microbial or laboratory data without outcome	1990-2021	292	Isolates
Literature studies	1990-2021	9,358	Cases/isolates/susceptibility tests

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>